Aurora Cannabis derives majority of revenue from outside Canada as medical sales accelerate

Aurora's 55% non-Canada revenue share underscores the company's international diversification amid domestic market maturation.

FILE — harvest · My 420 Tours / CC BY-SA 4.0

Aurora Cannabis is increasingly dependent on markets outside Canada, with 55% of revenue now generated internationally, according to Yahoo Finance reporting. The shift reflects both the maturation of the Canadian recreational market and the company's pivot toward higher-margin medical cannabis sales, which appear to be driving growth in jurisdictions where regulatory frameworks support prescription-based distribution.

The diversification comes as Canadian cannabis operators face a crowded domestic market and regulatory scrutiny. Related coverage notes that Israel recently reopened an anti-dumping investigation into Canadian medical cannabis imports, suggesting Aurora and peers may encounter tariff headwinds abroad. At the same time, regulatory wins—such as SNDL's EU-GMP facility audit in August—indicate pathways opening in traditional pharmaceutical markets where medical positioning could command premium valuations.

Watch whether Aurora's international revenue mix continues to expand or stabilizes as export markets tighten regulations and domestic competition intensifies. The company's ability to sustain margin growth overseas will likely determine whether the medical-focused international strategy can offset slow domestic volume growth.